On the Assessment of Drug Metabolism by Assays of Codeine and Its Main Metabolites
Authors:
- Emmanuel HaffenEHEmmanuel Haffen
- Gilles PaintaudGPGilles Paintaud
- Michel BerardMBMichel Berard
- Carole MasuyerCMCarole Masuyer
- Yvette BechtelYBYvette Bechtel
- Pierre R. BechtelPBPierre R. Bechtel
- 1 June 2000
- journal article
- Published by Wolters Kluwer Health in Therapeutic Drug Monitoring
- Vol. 22 (3) , 258-265
Abstract
Codeine and its main metabolites appear to have advantages for assessing drug metabolic phenotypes. The authors have further developed a high-performance liquid chromatography (HPLC) method for the quantification of codeine and six of its metabolites in urine. Quantification was performed by electrochemical detection for morphine, normorphine, morphine-6-glucuronide, and the internal standard 4-O-methyldopamine; and by ultraviolet detection for codeine, norcodeine, and morphine-3-glucuronide. The method had a detection limit of 2 nmol/L(-1) for morphine and normorphine, 4 nmol/L(-1) for morphine-6-glucuronide, 3 nmol/L for the internal standard, 20 nmol/L(-1) for morphine-3-glucuronide, and 60 nmol/L(-1) for codeine and norcodeine. The coefficients of variations were 0.95, p < 0.001). This HPLC method is simple, sensitive, accurate, and reproducible for assessing the CYP2D6 phenotype.Keywords
This publication has 36 references indexed in Scilit:
- MOLECULAR MECHANISMS OF GENETIC POLYMORPHISMS OF DRUG METABOLISMAnnual Review of Pharmacology and Toxicology, 1997
- Nomenclature for human CYP2D6 allelesPharmacogenetics, 1996
- “It's the genes, stupid” Molecular bases and clinical consequences of genetic cytochrome P450 2D6 polymorphismLife Sciences, 1995
- Hydroxylation polymorphisms of debrisoquine and mephenytoin in European populationsEuropean Journal of Clinical Pharmacology, 1990
- Codeine O‐demethylation co‐segregates with polymorphic debrisoquine hydroxylation.British Journal of Clinical Pharmacology, 1989
- Pharmacogenetics of dextromethorphan O-demethylation in manXenobiotica, 1986
- The genetic control of sparteine and debrisoquine metabolism in man with new methods of analysing bimodal distributions.Journal of Medical Genetics, 1983
- Polymorphic oxidation of sparteine and debrisoquine: Related pharmacogenetic entitiesClinical Pharmacology & Therapeutics, 1982
- Defective N-oxidation of sparteine in man: A new pharmacogenetic defectEuropean Journal of Clinical Pharmacology, 1979
- POLYMORPHIC HYDROXYLATION OF DEBRISOQUINE IN MANThe Lancet, 1977